6.
Burgel P, Ballmann M, Drevinek P, Heijerman H, Jung A, Mainz J
. Considerations for the use of inhaled antibiotics for in people with cystic fibrosis receiving CFTR modulator therapy. BMJ Open Respir Res. 2024; 11(1).
PMC: 11086488.
DOI: 10.1136/bmjresp-2023-002049.
View
7.
Natalini J, Singh S, Segal L
. The dynamic lung microbiome in health and disease. Nat Rev Microbiol. 2022; 21(4):222-235.
PMC: 9668228.
DOI: 10.1038/s41579-022-00821-x.
View
8.
Pallenberg S, Pust M, Rosenboom I, Hansen G, Wiehlmann L, Dittrich A
. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome. Microbiol Spectr. 2022; 10(5):e0145422.
PMC: 9602284.
DOI: 10.1128/spectrum.01454-22.
View
9.
Taylor-Cousar J, Robinson P, Shteinberg M, Downey D
. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023; 402(10408):1171-1184.
DOI: 10.1016/S0140-6736(23)01609-4.
View
10.
Gentzsch M, Mall M
. Ion Channel Modulators in Cystic Fibrosis. Chest. 2018; 154(2):383-393.
PMC: 6113631.
DOI: 10.1016/j.chest.2018.04.036.
View
11.
Warris A, Bercusson A, Armstrong-James D
. Aspergillus colonization and antifungal immunity in cystic fibrosis patients. Med Mycol. 2019; 57(Supplement_2):S118-S126.
DOI: 10.1093/mmy/myy074.
View
12.
Elborn J, Blasi F, Burgel P, Peckham D
. Role of inhaled antibiotics in the era of highly effective CFTR modulators. Eur Respir Rev. 2023; 32(167).
PMC: 9879329.
DOI: 10.1183/16000617.0154-2022.
View
13.
McDaniel M, Lindgren N, Billiot C, Valladares K, Sumpter N, Swords W
. Pseudomonas aeruginosa Promotes Persistence of Stenotrophomonas maltophilia via Increased Adherence to Depolarized Respiratory Epithelium. Microbiol Spectr. 2022; 11(1):e0384622.
PMC: 9927254.
DOI: 10.1128/spectrum.03846-22.
View
14.
Jones J, Morelli K, Vesely E, Puerner C, Pavuluri C, Ross B
. The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of biofilms. mBio. 2023; 14(5):e0151623.
PMC: 10653927.
DOI: 10.1128/mbio.01516-23.
View
15.
Goerke C, Matias y Papenberg S, Dasbach S, Dietz K, Ziebach R, Kahl B
. Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. J Infect Dis. 2004; 189(4):724-34.
DOI: 10.1086/381502.
View
16.
Bercusson A, Jarvis G, Shah A
. CF Fungal Disease in the Age of CFTR Modulators. Mycopathologia. 2021; 186(5):655-664.
PMC: 8536598.
DOI: 10.1007/s11046-021-00541-5.
View
17.
Hilliam Y, Armbruster C, Rapsinski G, Marshall C, Moore J, Koirala J
. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy. Microbiol Spectr. 2024; 12(8):e0078724.
PMC: 11302335.
DOI: 10.1128/spectrum.00787-24.
View
18.
Beck M, Hornick D, Pena T, Singh S, Wright B
. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis. Pediatr Pulmonol. 2023; 58(5):1569-1573.
DOI: 10.1002/ppul.26362.
View
19.
Martina M, Sannio F, Crespan E, Pavone M, Simoncini A, Barbieri F
. Towards Innovative Antibacterial Correctors for Cystic Fibrosis Targeting the Lung Microbiome with a Multifunctional Effect. ChemMedChem. 2022; 17(17):e202200277.
DOI: 10.1002/cmdc.202200277.
View
20.
Del Campo R, Morosini M, De la Pedrosa E, Fenoll A, Munoz-Almagro C, Maiz L
. Population structure, antimicrobial resistance, and mutation frequencies of Streptococcus pneumoniae isolates from cystic fibrosis patients. J Clin Microbiol. 2005; 43(5):2207-14.
PMC: 1153755.
DOI: 10.1128/JCM.43.5.2207-2214.2005.
View